Bgm (BGM) Liabilities and Shareholders Equity (2019 - 2025)
Bgm (BGM) posted quarterly Liabilities and Shareholders Equity of $433.8 million for Q3 2025, up 20485.23% year-over-year from N/an in Q3 2024, and up 109.17% quarter-over-quarter from $207.4 million in Q1 2025.
Bgm (BGM) Liabilities and Shareholders Equity (2019 - 2025) Analysis & Trends
Bgm (BGM) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $433.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Liabilities and Shareholders Equity rose 20485.23% year-over-year to $433.8 million; the TTM figure through Sep 2025 stood at $693.2 million (up 571.56% YoY), while the FY2025 annual figure was $433.8 million, up 20485.23% from the prior year.
- Liabilities and Shareholders Equity grew to $433.8 million in Q3 2025 per BGM's latest filing, from $207.4 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $433.8 million in Q3 2025 and bottomed at $64.23 in Q1 2023.
- Historically, Liabilities and Shareholders Equity has averaged $88.4 million across 5 years, with a median of $50.6 million in 2023.
- On a YoY basis, Liabilities and Shareholders Equity climbed as much as 77610725.48% in 2024 and fell as far as 95.89% in 2024.
- Bgm's Liabilities and Shareholders Equity stood at $75.4 million in 2021, then retreated by 14.37% to $64.5 million in 2022, then slipped by 20.56% to $51.3 million in 2023, then slumped by 95.89% to $2.1 million in 2024, then surged by 20485.23% to $433.8 million in 2025.
- Business Quant data shows BGM's Liabilities and Shareholders Equity at $433.8 million in Q3 2025, $207.4 million in Q1 2025, and $2.1 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 6.18 Bn |
| 10 | Bgm | 30.61 Mn | 20.79 Mn | - | 433.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 433.81 Mn |
| Mar 31, 2025 | 207.39 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 49.85 Mn |
| Sep 30, 2023 | 51.26 Mn |
| Mar 31, 2023 | 64.23 |
| Sep 30, 2022 | 64.53 Mn |
| Mar 31, 2022 | 80.15 |
| Sep 30, 2021 | 75.35 Mn |
| Mar 31, 2021 | 70.04 |
| Sep 30, 2020 | 48.14 Mn |
| Sep 30, 2019 | 35.27 Mn |